Search research articles
Contact Us
Filters
Showing results (11-20 of 56) with videos related to
Page
of 6
Sort By:
Cancer Chemotherapy and Pharmacology
|
September 23, 2015
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA)
Benoit You, Gilles Salles, Emmanuel Bachy, et al.
Cancer
|
June 16, 2010
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS)
Franck Morschhauser, Nicolas Mounier, Catherine Sebban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2008
Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study
Catherine Sebban, Pauline Brice, Richard Delarue, et al.
Blood
|
July 13, 2006
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Catherine Sebban, Nicolas Mounier, Nicole Brousse, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 17, 2008
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge
Catherine Sebban, Sophie Dussart, Christine Fuhrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome
Jean-François Larouche, Françoise Berger, Catherine Chassagne-Clément, et al.
Haematologica
|
January 2, 2016
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group
David Sibon, Franck Morschhauser, Matthieu Resche-Rigon, et al.
Hematological Oncology
|
February 6, 2014
Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up
Emmanuelle Nicolas-Virelizier, Céline Ségura-Ferlay, Herve Ghesquières, et al.
Bulletin Du Cancer
|
June 17, 2006
[Prognostic factors for febrile neutropenia]
Isabelle Ray-Coquard, Christophe Borg, Thomas Bachelot, et al.
British Journal of Haematology
|
April 28, 2016
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial
Ruth Pettengell, Catherine Sebban, Pier Luigi Zinzani, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 56) with videos related to
Sort By:
Page
of 6
Cancer Chemotherapy and Pharmacology
|
September 23, 2015
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA)
Benoit You, Gilles Salles, Emmanuel Bachy, et al.
Cancer
|
June 16, 2010
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS)
Franck Morschhauser, Nicolas Mounier, Catherine Sebban, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2008
Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study
Catherine Sebban, Pauline Brice, Richard Delarue, et al.
Blood
|
July 13, 2006
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Catherine Sebban, Nicolas Mounier, Nicole Brousse, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 17, 2008
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge
Catherine Sebban, Sophie Dussart, Christine Fuhrmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome
Jean-François Larouche, Françoise Berger, Catherine Chassagne-Clément, et al.
Haematologica
|
January 2, 2016
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group
David Sibon, Franck Morschhauser, Matthieu Resche-Rigon, et al.
Hematological Oncology
|
February 6, 2014
Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up
Emmanuelle Nicolas-Virelizier, Céline Ségura-Ferlay, Herve Ghesquières, et al.
Bulletin Du Cancer
|
June 17, 2006
[Prognostic factors for febrile neutropenia]
Isabelle Ray-Coquard, Christophe Borg, Thomas Bachelot, et al.
British Journal of Haematology
|
April 28, 2016
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial
Ruth Pettengell, Catherine Sebban, Pier Luigi Zinzani, et al.
Page
of 6